Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21087739 | 0.83 | CHRM3 (0.69) | CHRM2CHRM1CHRM3GAAATM | |
| SCHEMBL21088423 | 0.78 | CHRM2 (0.70) | CHRM2CHRM1CHRM3GAAATM | |
| SCHEMBL22484512 | 0.78 | CHRM2 (0.70) | CHRM2CHRM1CHRM3GAAATM | |
| SCHEMBL13398667 | 0.78 | CHRM2 (0.70) | CHRM2CHRM1CHRM3GAAATM | |
| SCHEMBL21052161 | 0.77 | NPC1 (0.44) | GAAALDH1A1NPC1RAB9A | |
| SCHEMBL13398649 | 0.76 | CHRM2 (0.67) | CHRM2CHRM1CHRM3GAAATM | |
| SCHEMBL13398950 | 0.75 | CHRM3 (1.00) | CHRM2CHRM1CHRM3GAAATM | |
| SCHEMBL22484503 | 0.75 | CHRM3 (1.00) | CHRM2CHRM1CHRM3GAAATM | |
| SCHEMBL7367520 | 0.74 | CHRNA7 (0.76) | CHRM2CHRM1CHRM3GAAATM | |
| SCHEMBL13399297 | 0.74 | CHRM2 (0.86) | CHRM2CHRM1CHRM3GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308168-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-10-01 | — | — | US | disclosed |
| WO-2019110521-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308168-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | CHRM2, CHRM3, CHRM5 | CHRM2 1/4885CHRM1 4/4885CHRM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.